Streetbeat News

Analyst Ratings

NEE

Morgan Stanley analyst David Arcaro maintains an Overweight rating on NextEra Energy and raises the price target from $87 to $90.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:14 pm

MGEE

Morgan Stanley has maintained an Underweight rating on MGE Energy while raising the price target from $71 to $74.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:13 pm

ABG

AN

F

GM

GPI

LAD

PAG

RIVN

SAH

Morgan Stanley analyst Adam Jonas downgraded Ford, GM, and Rivian due to concerns about the auto industry's outlook, including rising inventories and credit losses. Conversely, the firm upgraded several auto dealers, citing resilience and potential benefits from slower EV adoption.

Portfolio Pulse from Adam Eckert

September 25, 2024 | 4:12 pm

GEV

Morgan Stanley analyst Andrew Percoco reiterated a Buy rating on GE Vernova stock, increasing the price target. He highlights GE Vernova as a strong solution for AI data centers, suggesting Wall Street may be recognizing its potential.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:10 pm

CP

Barclays analyst Brandon Oglenski has maintained an Overweight rating on Canadian Pacific Kansas (NYSE:CP) and raised the price target from $95 to $97.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:08 pm

IDA

Morgan Stanley analyst David Arcaro maintains an Equal-Weight rating on Idacorp and raises the price target from $102 to $108.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:07 pm

FE

Morgan Stanley analyst David Arcaro maintains an Overweight rating on FirstEnergy (NYSE:FE) and raises the price target from $48 to $51.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:07 pm

CNI

Barclays analyst Brandon Oglenski has maintained an Equal-Weight rating on Canadian National Railway (NYSE:CNI) and slightly raised the price target from $120 to $121.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:06 pm

CLDX

Wolfe Research has reiterated its 'Outperform' rating for Celldex Therapeutics, maintaining a price target of $51. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:06 pm

EXC

Morgan Stanley analyst David Arcaro maintains an Equal-Weight rating on Exelon (NASDAQ:EXC) and raises the price target from $42 to $45.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 4:06 pm